Cytogenetic Testing in Newly Diagnosed Multiple Myeloma: Real World Evidence on Clinical Features and Adverse Outcomes for High Risk Groups
Clinical Lymphoma Myeloma and Leukemia · 2025
DOI: 10.1016/j.clml.2025.12.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Ghassan Zammar und 20 weiteren Autor:innen. Beteiligte Einrichtung: Haematology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia. Electronic address: Ghassan.Zammar@health.wa.gov.au. Hauptthemen laut MEDLINE: Multiple Myeloma, Cytogenetic Analysis. Die Arbeit nennt 37 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Haematology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia. Electronic address: Ghassan.Zammar@health.wa.gov.au.
- Haematology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
- School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
- Fiona Stanley Hospital, Perth, Western Australia, Australia.
- St Vincent's Hospital, Melbourne, Victoria, Australia.
- The Alfred Hospital, Melbourne, Victoria, Australia.
Zitieren
APA
Zammar, G., Augustson, B., Moore, E., Wellard, C., Ashrafi, E., Sidiqi, H., Lim, K. J. C., Radeski, D., Jackson, A., Bergin, K., Harrison, S., Ho, P. J., King, T., Quach, H., Mollee, P., Rajagopal, R., Rosengarten, B., Wood, E., McQuilten, Z., …, & Australian and New Zealand Myeloma and Related Diseases Registry investigators (2025). Cytogenetic Testing in Newly Diagnosed Multiple Myeloma: Real World Evidence on Clinical Features and Adverse Outcomes for High Risk Groups. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.12.005
Vancouver
Zammar G, Augustson B, Moore E, Wellard C, Ashrafi E, Sidiqi H, et al. Cytogenetic Testing in Newly Diagnosed Multiple Myeloma: Real World Evidence on Clinical Features and Adverse Outcomes for High Risk Groups. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.12.005
BibTeX
@article{Zammar2025,
author = {Zammar, Ghassan and Augustson, Bradley and Moore, Elizabeth and Wellard, Cameron and Ashrafi, Elham and Sidiqi, Hasib and Lim, Kenneth J C and Radeski, Dejan and Jackson, Alannah and Bergin, Krystal and Harrison, Simon and Ho, P Joy and King, Tracy and Quach, Hang and Mollee, Peter and Rajagopal, Rajeev and Rosengarten, Brian and Wood, Erica and McQuilten, Zoe and Spencer, Andrew and Australian and New Zealand Myeloma and Related Diseases Registry investigators, Australian and New Zealand Myeloma and Related Diseases Registry investigators},
title = {Cytogenetic Testing in Newly Diagnosed Multiple Myeloma: Real World Evidence on Clinical Features and Adverse Outcomes for High Risk Groups},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2025},
doi = {10.1016/j.clml.2025.12.005}
}
EUVIMED